Industry Regulatory and Market Trend Analysis of Combined Antigen Detection Kits for Metapneumovirus and Parainfluenza Virus

I. Product Classification and Registration Pathway: Class II or Class III Medical Device?

According to the Provisions for In Vitro Diagnostic Reagent Registration and the Classification Catalog, the metapneumovirus and parainfluenza virus antigen combined detection kit (latex chromatography method) belongs to microbial antigen detection reagents. Based on its intended use—for in vitro qualitative detection of viral antigens in human nasopharyngeal swab and other samples to assist in the diagnosis of acute respiratory infections—such products are generally regulated as Class II medical devices. However, if it includes newly discovered viral serotypes or employs an entirely novel detection principle, Class III registration may be required. Companies should conduct product classification determination before initiating development; if necessary, submit a classification application to the Center for Medical Device Standardization Administration of the National Medical Products Administration. The registration dossier must include raw material preparation, production processes, analytical performance evaluation (including limit of detection, cross-reactivity, precision, etc.), stability studies, and clinical evaluation data. As a mature technology, latex chromatography allows for relatively standardized performance verification, but attention must still be paid to anti-interference capability when performing parallel multi-target detection.

II. Key Points of Clinical Evaluation: How to Design Clinical Trials in Compliance with Regulations

According to the Provisions for the Registration and Filing of In Vitro Diagnostic Reagents, such reagents may follow an exemption pathway from clinical trials, provided that the product undergoes a clinical comparison study with an already marketed equivalent reagent (comparator reagent). Clinical samples should generally cover the target population (e.g., children with acute respiratory infections), include different viral load levels, and appropriately incorporate samples positive for other respiratory pathogens to assess cross-reactivity. For the combined detection of metapneumovirus and parainfluenza virus, the sensitivity and specificity of each target must be validated separately, and the concordance rate for dual-positive samples should also be reported. The primary sample type is generally nasopharyngeal swabs, though throat swabs, nasal washes, etc., may also be considered. Clinical evaluation should also address the impact of sample storage time and transport conditions on results.

III. Market Status and Competitive Landscape: Domestic Manufacturers and Import Substitution Trends

Currently, the domestic rapid respiratory antigen detection market is dominated by influenza virus and respiratory syncytial virus single or combination test products. Marketed products for the combined detection kit of metapneumovirus and parainfluenza virus are relatively few, representing a clear market gap. Although some imported brands (e.g., Alere, Becton Dickinson) have similar products, they are relatively expensive and have long registration cycles in China. Domestic companies such as Wondfo Biotech, Getein Biotech, and Autobio Diagnostics have already established a presence in the respiratory multiplex detection field. Leveraging the advantages of latex chromatography—controllable cost and relatively low technical barriers—they are expected to launch products with both price and performance competitiveness. With the increased demand for respiratory multi-pathogen surveillance in the post-pandemic era and the preference of medical insurance cost control for inexpensive yet effective consumables, the market penetration rate of such combined detection kits is expected to rise.

IV. Key Points of Regulatory Compliance: Precautions for Instructions for Use, Labels, and Advertising

According to the Provisions for the Administration of Medical Device Instructions and Labels, the product instructions should clearly specify the intended use, detection principle, main components, storage conditions, shelf life, test method, interpretation of results, limitations, etc. In advertising, claims such as "can replace nucleic acid testing" or "basis for confirmed diagnosis" should be avoided. Absolute expressions such as "only" or "most accurate" must not be used; the label "for in vitro diagnostic use only" should be indicated. Furthermore, if the product is used for clinical decision-making, it is recommended that the instructions clearly advise clinicians to make comprehensive judgments in conjunction with patient symptoms and other laboratory indicators. Manufacturing enterprises should also establish an adverse event monitoring system and promptly update the instructions based on real-world post-market use.